hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06342622, orgStudyIdInfo id: Weiguo Dong, briefTitle: Young-onset Colorectal Cancer Screening Based on Artificial Intelligence, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2024-01-10, completionDateStruct date: 2024-01-25, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Renmin Hospital of Wuhan University, class: OTHER, descriptionModule briefSummary: In this study, we aimed to develop, internally and temporally validate the machine learning models to help screen YOCRC bansed on the retrospective extracted Electronic Medical Records (EMR) data., conditionsModule conditions: Colorectal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 11000, type: ACTUAL, armsInterventionsModule interventions name: Using routine clinical data and machine learning models., outcomesModule primaryOutcomes measure: The performance of machine learning screening models, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 49 Years, stdAges: ADULT, contactsLocationsModule locations facility: Renmin Hospital of Wuhan University, city: Wuhan, state: Hubei, zip: 430060, country: China, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06342609, orgStudyIdInfo id: 32857-01-EKSTROM, briefTitle: Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease, acronym: EKSTROM, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-03-15, primaryCompletionDateStruct date: 2024-09-07, completionDateStruct date: 2024-09-07, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, class: OTHER, descriptionModule briefSummary: This is a randomized double-blind, placebo-controlled, investigator-initiated trial that compares Colchicine 0.5mg/day with placebo, among patients with stable CAD. Subjects will be educated to maintain medication compliance with other prescribed medications., conditionsModule conditions: Coronary Artery Disease, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Double blind Placebo controlled, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 84, type: ACTUAL, armsInterventionsModule interventions name: Colchicine 0.5 MG, outcomesModule primaryOutcomes measure: Rate of change in low attenuation plaque volume as measured by multidetector computed tomography (MDCT) angiography, secondaryOutcomes measure: Effect of Colchicine on markers of inflammation using laboratory tests, secondaryOutcomes measure: Effects of Colchicine on Pericoronary Adipose Tissue (PCAT) volume using CTA, secondaryOutcomes measure: Effects of Colchicine on Epicardial Adipose Tissue (EAT) volume using CTA, secondaryOutcomes measure: Effect of Colchicine on the markers of Endothelial Function using Flow-mediated dilation (FMD), eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, city: Torrance, state: California, zip: 90502, country: United States, geoPoint lat: 33.83585, lon: -118.34063, hasResults: False
protocolSection identificationModule nctId: NCT06342570, orgStudyIdInfo id: 3-2023-0462, briefTitle: Quantitative Analysis of EEG Changes in Response to Nociception, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-18, primaryCompletionDateStruct date: 2026-12-30, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Gangnam Severance Hospital, class: OTHER, descriptionModule briefSummary: This study will quantify the nociception using Analgesia Nociception Index (ANI) during general anesthesia and analyze the differences in EEG depending on the degree of nociception. Additionally, the investigators will quantify the nociception during recovery and analyze the differences in EEG depending on the degree of nociception., conditionsModule conditions: Patients Undergoing Laparoscopic Surgery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 109, type: ESTIMATED, armsInterventionsModule interventions name: There is no Intervention name to describe., outcomesModule primaryOutcomes measure: Correlation between changes in ANI and EEG band power in response to surgical stimulation., secondaryOutcomes measure: Correlation between changes in ANI and EEG band power in response to tracheal intubation, secondaryOutcomes measure: Correlation between changes in ANI and EEG connectivity in response to surgical stimulation, secondaryOutcomes measure: Correlation between changes in ANI and EEG connectivity in response to tracheal intubation, secondaryOutcomes measure: Correlation between changes in ANI, EEG band power and NRS in response to analgesic administration, secondaryOutcomes measure: Correlation between changes in ANI, EEG connectivity and NRS in response to analgesic administration, secondaryOutcomes measure: Differences in EEG band power(Delta, Theta, Alpha, Beta, Gamma) during surgery between groups with large and small changes in ANI, secondaryOutcomes measure: Differences in EEG connectivity during surgery between groups with large and small changes in ANI, secondaryOutcomes measure: Differences in EEG band power(Delta, Theta, Alpha, Beta, Gamma) during recovery between groups with large and small changes in ANI, secondaryOutcomes measure: Differences in EEG connectivity during recovery between groups with large and small changes in ANI, secondaryOutcomes measure: Differences in EEG band power(Delta, Theta, Alpha, Beta, Gamma) depending on the type of inhaled anesthetic, secondaryOutcomes measure: Differences in EEG connectivity depending on the type of inhaled anesthetic, secondaryOutcomes measure: Differences in ANI depending on the type of inhaled anesthetic, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: GangnamSeverance Hospital, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Myung Il Bae, role: CONTACT, phone: 82-2-2019-6611, email: BMI87@yuhs.ac, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06342557, orgStudyIdInfo id: FROM, briefTitle: Transitional ePRO Diary Liver, acronym: MACROLIVER, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2034-02-21, completionDateStruct date: 2034-02-21, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, class: OTHER, descriptionModule briefSummary: The study is part of the MACROLIVER Project, whose main objective is to create a digital tool for patients and caregivers for the management of liver disease that allows the optimization of therapy and/or the treatment process, even remotely. Such a tool not only reduces the movement of patients who are by definition fragile, but also enables the optimization of access and care by a multidisciplinary team. This tool is intended to support doctors and patients, but in no way replaces normal clinical practice. This study aims to explore the specificities of patients experiencing the transition from the pediatric ward to the adult ward in order to identify risk and protective factors that influence psychological well-being at both an individual and relational level. In order to gather all the information about the patients attending the transitional clinic and to obtain a more complete and truthful clinical-psychological picture, the study also includes the collection of retrospective data of the transplanted patients., conditionsModule conditions: Liver Transplant, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 250, type: ESTIMATED, outcomesModule primaryOutcomes measure: four-item Morisky Medication Adherence Scale (MGLS), eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 20 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: ASST-Papa Giovanni XXIII, status: RECRUITING, city: Bergamo, state: Milano, zip: 24127, country: Italy, contacts name: Stefano Fagiuoli, MD, role: CONTACT, phone: 035.2674259, email: sfagiuoli@asst-pg23.it, geoPoint lat: 45.69601, lon: 9.66721, hasResults: False
protocolSection identificationModule nctId: NCT06342531, orgStudyIdInfo id: 210324, briefTitle: More Effective Violence Risk Management - eDASA+APP FI, acronym: eDASA+APP FI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: University of Turku, class: OTHER, collaborators name: Helsinki University Central Hospital, descriptionModule briefSummary: The main goal of this study is to evaluate if the Finnish version of eDASA+APP (electronic Dynamic Appraisal of Situational Aggression + Aggression Prevention Protocol), a clinical decision support system (CDSS), has an impact on reducing workplace violence, use of coercive measures and increasing nurses' job satisfaction in adult psychiatric inpatient care., conditionsModule conditions: Violence, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: A pre-post design (quasi-experimental), a cluster design, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 26, type: ESTIMATED, armsInterventionsModule interventions name: eDASA+APP FI, outcomesModule primaryOutcomes measure: Workplace violence, secondaryOutcomes measure: Coercive measures, secondaryOutcomes measure: Job satisfaction, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06342518, orgStudyIdInfo id: MU ESWT, briefTitle: ESWT in Lateral Epicondylitis: Clinical,Ultrasonographic Evaluation, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-12-01, primaryCompletionDateStruct date: 2021-09-01, completionDateStruct date: 2021-12-01, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Istanbul Medeniyet University, class: OTHER, descriptionModule briefSummary: This study aimed to check and compare how well shock wave therapy works for tennis elbow, both in terms of symptoms and what we can see on ultrasound., conditionsModule conditions: Lateral Epicondylitis, conditions: Tennis Elbow, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 42, type: ACTUAL, armsInterventionsModule interventions name: Extracorporeal Shock Wave Therapy (ESWT), interventions name: Sham ESWT, interventions name: Resting Splint, Exercises and ice, outcomesModule primaryOutcomes measure: Hand Grip Strength, primaryOutcomes measure: Pain severity, primaryOutcomes measure: Functionality, primaryOutcomes measure: Quality of life score, primaryOutcomes measure: deep muscular tissue sensitivity, primaryOutcomes measure: thickness of the common extensor tendon (CET), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Istanbul Medeniyet University Faculty of Medicine, Physical Medicine and Rehabilitation Department, city: Istanbul, zip: 34732, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06342505, orgStudyIdInfo id: MEC-2022-0037, briefTitle: Tacrolimus in CD3+ T Lymphocytes, acronym: INTACT, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-05-30, primaryCompletionDateStruct date: 2022-10-10, completionDateStruct date: 2022-11-10, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Erasmus Medical Center, class: OTHER, descriptionModule briefSummary: The goal of this study is to measure concentrations of the drug tacrolimus in both whole blood and within T lymphocytes. It will also learn on the correlation between the concentration in T lymphocytes and the effects of the drug. The main questions are:(i) What is the ratio between the tacrolimus concentration within T lymphocytes and in whole blood?; (ii) What is the correlation between tacrolimus concentrations and the effects of the drug?Participants will:* Receive standard clinical care;* Undergo two extra venipunctures for the collection of blood., conditionsModule conditions: Immunosuppression, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 28, type: ACTUAL, armsInterventionsModule interventions name: Venipunctures, outcomesModule primaryOutcomes measure: The intracellular tacrolimus concentration in CD3+ T lymphocytes, secondaryOutcomes measure: Intracellular cytokine production, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erasmus MC, city: Rotterdam, zip: 3015 GD, country: Netherlands, geoPoint lat: 51.9225, lon: 4.47917, hasResults: False
protocolSection identificationModule nctId: NCT06342492, orgStudyIdInfo id: KCHRRF_CS Lead Failure_0025, briefTitle: Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Kansas City Heart Rhythm Research Foundation, class: OTHER, descriptionModule briefSummary: This a single-center, retrospective, observational study of patients that undergo coronary sinus(CS) lead revision, comparing epicardial lead placement to coronary sinus pacing(CSP) in those that had lead failure., conditionsModule conditions: Heart Failure With Reduced Ejection Fraction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Coronary Sinus Lead Revision, outcomesModule primaryOutcomes measure: Need for lead revision, secondaryOutcomes measure: Electrocardiography characteristics - QRS Interval, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Menorah Medical Center, city: Overland Park, state: Kansas, zip: 66209, country: United States, geoPoint lat: 38.98223, lon: -94.67079, locations facility: Kansas City Heart Rhythm Institute - Roe Clinic, city: Overland Park, state: Kansas, zip: 66211, country: United States, geoPoint lat: 38.98223, lon: -94.67079, locations facility: Overland Park Regional Medical Center, city: Overland Park, state: Kansas, zip: 66215, country: United States, geoPoint lat: 38.98223, lon: -94.67079, locations facility: Centerpoint Medical Center Clinic, city: Independence, state: Missouri, zip: 64057, country: United States, geoPoint lat: 39.09112, lon: -94.41551, locations facility: Centerpoint Medical Center, city: Independence, state: Missouri, zip: 64057, country: United States, geoPoint lat: 39.09112, lon: -94.41551, locations facility: Research Medical Center Clinic, city: Kansas City, state: Missouri, zip: 64032, country: United States, geoPoint lat: 39.09973, lon: -94.57857, locations facility: Research Medical Center, city: Kansas City, state: Missouri, zip: 64032, country: United States, geoPoint lat: 39.09973, lon: -94.57857, hasResults: False
protocolSection identificationModule nctId: NCT06342479, orgStudyIdInfo id: NM: 04.20.ND:30.03.2023, briefTitle: Discharge Training for Patients With Intertrochanteric Fracture, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Erzurum Technical University, class: OTHER, descriptionModule briefSummary: This study examines the effect of discharge training given to patients with intertrochanteric femur fractures on the wound healing process and readiness for discharge. In the study, patients were provided with certain educational content before and after discharge. The effect of training on wound healing, readiness for discharge and post-discharge recovery process will be evaluated statistically., conditionsModule conditions: Surgical Wound, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Discharge Education, outcomesModule primaryOutcomes measure: Toronto Wound Symptom Assessment System, secondaryOutcomes measure: Discharge readiness scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erzurum Technical University Faculty of Health Sciences, status: RECRUITING, city: Erzurum, zip: 25000, country: Turkey, contacts name: Yasemin Erden, role: CONTACT, phone: 05303461516, email: yasemin.erden@erzurum.edu.tr, geoPoint lat: 39.90861, lon: 41.27694, hasResults: False
protocolSection identificationModule nctId: NCT06342466, orgStudyIdInfo id: 2023-358-02, briefTitle: Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Jin Lu, MD, class: OTHER, descriptionModule briefSummary: This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months., conditionsModule conditions: Systemic Amyloidosis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Bortezomib, pomalidomide, dexamethasone, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Bortezomib, interventions name: Pomalidomide, interventions name: Dexamethasone, outcomesModule primaryOutcomes measure: Hematologic VGPR + CR rate at 6 months, secondaryOutcomes measure: Overall Hematologic response rate at 6 months, secondaryOutcomes measure: At least one organ response at 6 months, secondaryOutcomes measure: TTNT at 2 years, secondaryOutcomes measure: Estimated PFS at 2 years, secondaryOutcomes measure: Estimated OS at 2 years, secondaryOutcomes measure: TRAE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University People's Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100044, country: China, contacts name: Yang Liu, role: CONTACT, phone: +8613716926210, email: pkuphliuyang@bjmu.edu.cn, contacts name: Jin Lu, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06342427, orgStudyIdInfo id: 23228/DESTINEX, briefTitle: Stomach Cancer Exosome-based Detection, acronym: DESTINEX, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-15, primaryCompletionDateStruct date: 2025-03-15, completionDateStruct date: 2025-03-15, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: City of Hope Medical Center, class: OTHER, descriptionModule briefSummary: Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer., conditionsModule conditions: Gastric Cancer, conditions: Gastric Adenocarcinoma, conditions: Gastric Cancer Stage, conditions: Gastric Neoplasm, conditions: Gastric Lesion, conditions: Gastric Cancer in Situ, conditions: Gastric Cancer Stage IV, conditions: Gastric Cancer Stage IIIB, conditions: Gastric Cancer Stage III, conditions: Gastric Cancer Stage IB, conditions: Gastric Cancer Stage IA, conditions: Gastric Cancer, Stage 0, conditions: Gastric Cancer Stage IIIA, conditions: Gastric Cancer Stage II, conditions: Gastric Cancer TNM Staging, conditions: Gastric Cancer Metastatic to Lung, conditions: Gastric Cancer Metastatic to Liver, conditions: Gastric Cancer Stage I, conditions: Gastric Cancer TNM Staging Primary Tumor (T) T2B, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 800, type: ESTIMATED, armsInterventionsModule interventions name: DESTINEX, outcomesModule primaryOutcomes measure: Sensitivity, secondaryOutcomes measure: Specificity, secondaryOutcomes measure: Proportion of correct predictions (true positives and true negatives) among the total cases (i.e., accuracy), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: City of Hope Medical Center, status: RECRUITING, city: Duarte, state: California, zip: 91010, country: United States, contacts name: Ajay Goel, PhD, role: CONTACT, phone: 626-218-3452, email: AJGOEL@COH.ORG, contacts name: Silei Sui, role: PRINCIPAL_INVESTIGATOR, contacts name: Caiming Xu, role: SUB_INVESTIGATOR, contacts name: Ajay Goel, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.13945, lon: -117.97729, locations facility: Nagoya University, status: RECRUITING, city: Nagoya, country: Japan, contacts name: Yasuhiro Kodera, role: CONTACT, contacts name: Yasuhiro Kodera, role: SUB_INVESTIGATOR, contacts name: Mitsuo Kanda, role: SUB_INVESTIGATOR, geoPoint lat: 35.18147, lon: 136.90641, locations facility: Mie University, status: RECRUITING, city: Tsu, country: Japan, contacts name: Yuji Toiyama, role: CONTACT, contacts name: Yuji Toiyama, role: SUB_INVESTIGATOR, contacts name: Yoshinaga Okugawa, role: SUB_INVESTIGATOR, geoPoint lat: 34.73333, lon: 136.51667, hasResults: False